指南与共识腹部介入技术与安全US

超声引导高强度聚焦超声治疗胰腺癌:中国与欧洲HIFU中心共识倡议

US-guided high-intensity focused ultrasound in pancreatic cancer treatment: a consensus initiative between Chinese and European HIFU centers.
指南 / 共识 · Int J Hyperthermia · 2023-12-30

该共识由中国与欧洲HIFU中心合作制定,明确超声引导高强度聚焦超声(USgHIFU)用于不可手术胰腺癌患者的选择标准、禁忌证、终点指标及并发症。共识认为USgHIFU应作为全身化疗或最佳支持治疗的辅助选项,用于缓解疼痛和减小肿瘤体积。

要点

  • USgHIFU主要用于不可切除的局部晚期或转移性胰腺癌,尤其因局部晚期原发肿瘤出现症状者。
  • USgHIFU可缓解疼痛、减小原发肿瘤体积,应作为症状性不可手术患者的补充治疗。
  • 共识定义了患者选择标准、禁忌证、副作用与并发症,并探讨了姑息治疗中的可行性。

核心结论

  • USgHIFU作为非侵入性局部治疗,是化疗和最佳支持治疗的补充,在镇痛、减小肿瘤体积及可能改善生存率方面起关键作用。

研究设计与样本

  • 中国与欧洲HIFU中心合作的共识文件,基于现有证据(缺乏随机对照试验)制定患者选择标准、终点指标及禁忌证。

诊断标准与关键数值

  • 适应证:不可切除、局部晚期或转移性胰腺癌,尤其因局部晚期原发肿瘤出现症状者。
  • 终点指标包括症状缓解、局部缓解率、其他肿瘤学结局及总生存和无进展生存。
  • 共识定义了USgHIFU相关禁忌证、副作用和并发症。

临床应用与阅片要点

  • 共识提出USgHIFU应被视为全身化疗或最佳支持治疗的辅助选项。
  • 作者认为USgHIFU可考虑作为症状性不可手术胰腺癌患者的补充治疗及肿瘤减容的潜在手段。
  • 共识文件可能作为医学界的指导资源,专家应评估该治疗选择。

局限性

  • 现有证据受限于缺乏随机对照试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose: Ultrasound-guided high-intensity focused ultrasound (USgHIFU) represents a safe and effective non-invasive thermoablative technique for managing inoperable pancreatic cancer. This treatment method significantly alleviates disease-related symptoms and reduces pancreatic tumor volume. However, the current body of evidence is constrained by a lack of randomized controlled trials. The utilization of USgHIFU is primarily indicated for patients with unresectable, locally advanced, or metastatic pancreatic cancer, particularly those experiencing symptoms due to a locally advanced primary tumor.Methods: This collaborative consensus paper, involving European and Chinese HIFU centers treating pancreatic cancer, delineates criteria for patient selection, focusing on those most likely to benefit from USgHIFU treatment. Consideration is given to endpoints encompassing symptom alleviation, local response rates, other oncological outcomes, as well as overall and progression-free survival. Additionally, this paper defines relevant contraindications, side effects, and complications associated with USgHIFU. The publication also explores the feasibility and role of USgHIFU within the context of palliative care, including standard systemic chemotherapy.Results: The non-invasive local treatment of advanced pancreatic cancer using HIFU should be regarded as an adjunctive option alongside systemic chemotherapy or best supportive care for managing this aggressive disease. Based on the ability of USgHIFU therapy to mitigate pain and reduce primary tumor volume, it should be considered as a complementary therapy for symptomatic patients with inoperable pancreatic cancer and as a potential means of tumor debulking. The underutilized yet promising USgHIFU exhibits the potential to enhance patients' quality of life by alleviating cancer-related pain. Experts in the field should evaluate this treatment option be evaluated by experts in this field, with this consensus paper potentially serving as a guiding resource for the medical community.Conclusions: US-guided HIFU for advanced pancreatic cancer addresses treatment goals, available options, success rates, and limitations. As a non-invasive, effective local therapy, complementary to chemotherapy and best supportive care, it plays a pivotal role in pain relief, reducing of tumor volume, and potentially improving survival rates.

来源:Int J Hyperthermia,查看原文。版权归原作者所有。

引用

  1. Zhou K, Strunk H, Dimitrov D, et al. US-guided high-intensity focused ultrasound in pancreatic cancer treatment: a consensus initiative between Chinese and European HIFU centers. Int J Hyperthermia. 2023. PMID: 38159562. doi:10.1080/02656736.2023.2295812

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。